A US district court did not err in ruling that two US patents shielding Bristol Myers Squibb and Pfizer’s Eliquis (apixaban) blockbuster were valid and infringed by abbreviated new drug applications filed by HEC’s Sunshine Lake Pharma, Sigmapharm and Unichem, the US Court of Appeals for the Federal Circuit has affirmed.
The Federal Circuit’s decision – which was issued after it deduced “no error, and certainly no clear error, in the...






